Pharmaceutical heavyweight Mylan, the latest poster child for drug-industry greed, finally stuck up for itself Thursday. It argued that “the system,” not avarice, was to blame for the company jacking up the price of EpiPens, a common (and life-saving) allergy remedy, by over 400%.
“Look, no one’s more frustrated than me,” Mylan Chief Executive Heather Bresch declared on CNBC.
20:43 California just added four more ‘discriminatory’ states to its travel ban13
20:47 Trump’s putdown of wind energy whips up a backlash in Iowa27
14:46 Russia slashes spending on cancer drugs amid skyrocketing prices: Report10
23:23 Uber is a Creature of an Industry Struggling to Grow Up22